Novel Therapeutic Approach for Human T-cell Malignancies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Translation analysis.
- Who it may be relevant to
- Registry conditions: T-Cell Leukemia/Lymphoma, Adult. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Identification of Targetable Vulnerabilities in Redox Homeostasis Pathways as a Novel Therapeutic Approach for Human T-cell Malignancies
Overview
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
Interventions
- Other Translation analysis
Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
Primary outcome measures
- Primary outcome [Time frame: Through study completion, an average of 2 years]
Secondary outcome measures (3)
- Secondary outcome [Time frame: Through study completion, an average of 2 years]
- Secondary outcome [Time frame: Through study completion, an average of 2 years]
- Secondary outcome [Time frame: Through study completion, an average of 2 years]
Eligibility criteria
Inclusion criteria
- Patients with pre- and post-thymic T-cell leukemia/lymphoma
- Patients of both sexes
- Age of patients older than 18 years
- Patient is willing to provide written and signed informed consent for participation in the study
Exclusion criteria
-Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Italy · 2 centers
- Istituto Nazionale Tumori Fondazione G.Pascale — Naples
- Istituto Oncologico Veneto — Padova
Identifiers
NCT: NCT06600568 · ROSinTALL